Yale University
Nuformix proposes acquisition of Biovara
The companies focus on fibrosis and oncology, and novel treatments for respiratory conditions, respectively
AstraZeneca and Daiichi Sankyo to collaborate with Summit Therapeutics
This builds on a recently announced clinical collaboration between AstraZeneca and Summit to advance cancer treatments
Smarter science, sharper strategy: Expert insights from ASCO® 2026
As the oncology landscape continues to evolve, life sciences organizations face a growing challenge: how do you communicate increasingly complex science in a way that creates meaningful engagement?
US FDA accepts supplemental Biologics License Application for Merck’s Enflonsia
The treatment is to protect children under two years of age from respiratory syncytial virus
Permission to pause: making treatment breaks part of the cancer care conversation
Exploring how empathetic, patient-centred communication can make planned treatment breaks easier to discuss as part of cancer care.
Key takeaways from ASCO® 2026
Following ASCO® 2026, Inizio's experts have shared their perspectives across three thought leadership articles, each exploring a different aspect of what this year's congress revealed for pharmaceutical organisations. Together, they...
Webcast | Smarter science, sharper strategy: Expert perspectives from ASCO® 2026
Key insights from ASCO® 2026, including oncology trends, scientific highlights, and strategies for smarter congress engagement.
Pfizer and Innovent Biologics agree on deal worth up to $10.5bn
The companies plan to research and develop 12 new cancer treatments
One-carbon Therapeutics collaborates with Tempus in cancer treatment
The treatment is currently being evaluated in a phase 1/2 multicentre clinical study
Gilead to acquire Tubulis for up to $5bn
The acquisition builds on Gilead’s oncology pipeline, focused on addressing areas of high unmet need
Merck agrees on $2.2bn deal with Quotient Therapeutics to develop IBD treatment
Quotient’s somatic genomics platform technology will be used to develop the treatment
Moderna and Merck announce data from melanoma combination therapy study
Skin cancer is one of the most common cancers in the US, with melanoma accounting for the majority of skin cancer deaths